311PEarly results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC).

Autor:	Shum, M1 (AUTHOR), Assikis, V J2 (AUTHOR), Savulsky, C3 (AUTHOR), Zhu, W4 (AUTHOR), Iyer, P4 (AUTHOR), Xing, D5 (AUTHOR), Berman, C6 (AUTHOR), Lokker, N A6 (AUTHOR), Alvarez, R H7 (AUTHOR)
Zdroj:	Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu